Published in J Clin Invest on February 01, 1973
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
Selective triggering of human T and B lymphocytes in vitro by polyclonal mitogens. J Exp Med (1974) 3.39
Identification of human B and T lymphocytes by scanning electron microscopy. J Exp Med (1973) 3.21
Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes. J Exp Med (1974) 3.21
Human lymphocyte subpopulations. Effect of corticosteroids. J Clin Invest (1974) 2.96
Characterizaiton of two populations of human lymphocytes bearing easily detectable surface immunoglobulin. J Clin Invest (1975) 2.78
Specificity of human lymphocyte complement receptors. J Exp Med (1975) 2.77
Stages of B cell differentiation in human lymphoid tissue. J Exp Med (1981) 2.49
Human lymphocytes bear membrane receptors for C3b and C3d. J Clin Invest (1973) 2.46
Sheep red cell binding to human lymphocytes treated with neuraminidase; enhancement of T cell binding and identification of a subpopulation of B cells. J Exp Med (1973) 2.37
Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism. J Exp Med (1974) 2.22
Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus. J Clin Invest (1973) 2.19
Ontogeny of B lymphocytes. II. Relative rates of appearance of lymphocytes bearing surface immunoglobulin and complement receptors. J Exp Med (1974) 2.03
A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest (1981) 1.93
Interaction of peanut agglutinin with normal human lymphocytes and with leukemic cells. Proc Natl Acad Sci U S A (1979) 1.74
T and B lymphocytes in peripheral blood and tissue lesions in Sjögren's syndrome. J Clin Invest (1974) 1.63
Studies of peripheral blood T-and B-lymphocytes in acute infections. Infect Immun (1974) 1.58
In vitro synthesis of some complement components (C1q, C3 and C4) by lymphoid tissues and circulating leucocytes in man. Immunology (1975) 1.50
Rosette formation with mouse erythrocytes defines a population of human B lymphocytes unresponsive to pokeweed mitogen. Clin Exp Immunol (1981) 1.48
Human peripheral lymphocytes bearing both B-cell complement receptors and T-cell characteristics for sheep erythrocytes detected by a mixed rosette method. Clin Exp Immunol (1974) 1.40
Heterologous specific antiserum for identification of human T lymphocytes. Clin Exp Immunol (1974) 1.40
Rosette formation by mouse lymphocytes. II. T-cell specificities in a CRL subpopulation. Clin Exp Immunol (1974) 1.39
Formation of auto-rosettes by peripheral blood lymphocytes. Clin Exp Immunol (1975) 1.37
A morphologic and immunologic surface marker study of 299 cases of non-Hodgkin lymphomas and related leukemias. Am J Pathol (1978) 1.33
Enumeration and isolation of human T and B lymphocytes by rosette formation with antibody-coated erythrocytes. Clin Exp Immunol (1975) 1.32
Malignant lymphomas--a conceptual understanding of morphologic diversity. A review. Am J Pathol (1979) 1.30
Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci U S A (1976) 1.20
E and EAC rosetting lymphocytes in patients with carcinoma of bronchus I. Some parameters of the test and of its prognostic significance. Clin Exp Immunol (1975) 1.17
B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease. J Clin Invest (1973) 1.17
Receptors for activated C3 on thymus-dependent (T) lymphocytes of normal guinea-pigs. Immunology (1979) 1.13
PHA stimulation of separated human lymphocyte populations. Clin Exp Immunol (1975) 1.12
Inhibition by C3 fragments of C3-dependent rosette formation and antigen-induced lymphocyte transformation. Clin Exp Immunol (1974) 1.11
Human lymphocyte subpopulations effect of epinephrine. Clin Exp Immunol (1976) 1.10
Age-dependent changes of human blood lymphocyte subpopulations. Clin Exp Immunol (1978) 1.10
T and B lymphocytes in multiple sclerosis. Clin Exp Immunol (1975) 1.09
Rosette formation with mouse erythrocytes. III. Studies in patients with primary immunodeficiency and lymphoproliferative disorders. Clin Exp Immunol (1976) 1.07
Development of lymphocyte populations in the human foetal thymus and spleen. Clin Exp Immunol (1974) 1.06
C3-mediated cytoadherence. Formation of C3 receptor aggregates as prerequisite for cell attachment. J Exp Med (1975) 1.04
Surface markers of complement receptor lymphocytes. J Clin Invest (1978) 1.03
Heterogeneity of stem cells in severe combined immunodeficiency. Clin Exp Immunol (1976) 1.03
Surface marker and other characteristics of Gaucher's cells. J Clin Pathol (1977) 1.01
Cellular immunology in the pig. Proc R Soc Med (1973) 1.00
Membrane receptor sites for the identification of lymphoreticular cells in benign and malignant conditions. Br J Cancer Suppl (1975) 0.99
Studies on the immune status of children with acute lymphocytic leukaemia. I. Early phase before and after first remission. Clin Exp Immunol (1976) 0.99
Lymphocytes bearing complement receptors, surface immunoglobulins and sheep erythrocyte receptors in primary immunodeficiency diseases. Clin Exp Immunol (1974) 0.99
A human leukemia cell with both B and T cell surface receptors. Proc Natl Acad Sci U S A (1974) 0.98
Inhibition of T- and B-lymphocyte functions by normal immunosuppressive protein. Immunology (1975) 0.98
Separation of T lymphocytes from normal individuals and patients with B lymphocyte chronic lymphocytic leukaemia. Immunology (1975) 0.97
Lymphocyte subpopulation in neoplastic and non-neoplastic thymus and in blood of patients with Myasthenia gravis. Clin Exp Immunol (1976) 0.97
Morphological, immunological and immunocytochemical identification of lymphocytes extracted from cutaneous infiltrates. Clin Exp Immunol (1976) 0.97
Lymphocyte emperipolesis revisited. I. Development of in vitro assay and preliminary characterisation of the lymphocyte subpopulation involved. Immunology (1978) 0.97
Rosette formation by mouse lymphocytes. IV. Fc and C3 receptors occurring together and separately on T cells and other leucocytes. Clin Exp Immunol (1975) 0.95
Phytohemagglutinin response in systemic lupus erythematosus. Reconstitution experiments using highly purified lymphocyte subpopulations and monocytes. J Clin Invest (1977) 0.94
Assessment of cellular and humoral immunity of myasthenics. J Neurol Neurosurg Psychiatry (1977) 0.92
Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox). Clin Exp Immunol (1977) 0.91
T and B lymphocytes in humans. A review. Am J Pathol (1975) 0.91
Plaque-forming cells in human cord blood: studies on T and B cell function. Clin Exp Immunol (1980) 0.90
Morphology of lymphatic cells and of their derived tumours. J Clin Pathol (1978) 0.90
Bovine lymphocytes: recognition of cells forming spontaneous (E) rosettes. Clin Exp Immunol (1977) 0.90
Maturation of bone marrow lymphocytes. II. Development of Fc and complement receptors and surface immunoglobulin studied by rosetting and radioautography. J Exp Med (1978) 0.89
T lymphocytes bearing complement receptors in a patient with chronic lymphocytic leukaemia. Clin Exp Immunol (1977) 0.88
Surface antigenic specificities of human thymus-derived lymphocytes. Clin Exp Immunol (1975) 0.86
Thymic hormonal activity on human peripheral blood lymphocytes, in vitro. I. Reciprocal effect on T and B rosette formation. Immunology (1980) 0.85
T-cell and B-cell identification in the diagnosis of lymphoproliferative disease. A review. Am J Pathol (1977) 0.84
Antigen heterogeneity of human B and T lymphocytes. J Clin Invest (1976) 0.83
Effect of corticosteroids on exercise-induced lymphocytosis. Clin Exp Immunol (1977) 0.82
Leucapheresis in severe rheumatoid arthritis. Ann Rheum Dis (1979) 0.82
Surface markers on lymphocytes of multiple sclerosis patients. Clin Exp Immunol (1975) 0.81
Receptors for immunoglobulin isotype on T and B lymphocytes from untreated patients with chronic lymphocytic leukaemia. Clin Exp Immunol (1980) 0.80
Chronic lymphocytic leukemia cells lack the 185,000-dalton macromolecular insoluble cold globulin present on normal B lymphocytes. J Clin Invest (1981) 0.79
Use of cryopreserved cells in quality control of human lymphocyte assays: analysis of variation and limits of reproducibility in long-term replicate studies. Clin Exp Immunol (1979) 0.79
Functional and phenotypic heterogeneity of electrophoretically separated leukaemic B cells from patients with chronic lymphocytic leukaemia. Clin Exp Immunol (1985) 0.78
Synthesis and secretion of cystic fibrosis ciliary dyskinesia substances by purified subpopulations of leukocytes. J Clin Invest (1980) 0.78
Absence of a receptor for fixed C3 on the hairy cells of leukaemic reticuloendotheliosis. Clin Exp Immunol (1977) 0.78
Expression of Fc and complement receptors on T lymphocytes activated in vitro by phytohaemagglutinin (PHA). Immunology (1977) 0.77
A case of small-cell Sézary's syndrome with null-cell features. J Clin Pathol (1976) 0.77
Human lymphocyte complement receptors. Quantitative requirements for C3 of normal and chronic lymphocyte leukemia lymphocytes. J Clin Invest (1977) 0.76
Binding of bacteria from the genus Brucella to human B lymphocytes. Infect Immun (1981) 0.76
Studies in chronic lymphocytic leukaemia II. Lymphocyte markers, cellular and humoral immunity and the effect of treatment. Postgrad Med J (1980) 0.75
Immunocompetent cells in malignant disease in man. II. Clinical and immunologic correlates in a case of non-Hodgkin's lymphoma. Can Med Assoc J (1978) 0.75
Antiserums for immunofluorescent enumeration of human T lymphocytes utilizing fluoresceinated staphylococcal protein A. Am J Pathol (1978) 0.75
Immunologic abnormalities in a patient with multiple neoplasms. Can Med Assoc J (1976) 0.75
Rheumatoid rosette in juvenile rheumatoid arthritis. Arch Dis Child (1974) 0.75
Factors inducing a loss of net negative surface charge on spleen cells of mice grafted with a slow-growing tumour. Br J Cancer (1980) 0.75
A sub-set of murine T lymphocytes forming rosettes with rabbit erythrocytes. Immunology (1980) 0.75
The antibody-independent cytotoxic activity of normal circulating human leucocytes. I. Lysis of target cells by monocytes and neutrophils in a non-phagocytic pathway. Immunology (1981) 0.75
The response to lipopolysaccharide of mouse spleen lymphocytes fractionated on the basis of surface immunoglobulin and complement receptor using fluorescence-activated cell sorting and rosetting techniques. Immunology (1979) 0.75
Acute lymphoblastic leukaemia of the B-cell type refractory to intensive chemotherapy. Clin Exp Immunol (1978) 0.75
Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med (1972) 24.43
A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med (1970) 15.86
ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 15.47
Immunoglobulin determinants on the surface of mouse lymphoid cells. Nature (1970) 8.35
Immunoglobulins on the surface of lymphocytes. I. Distribution and quantitation. J Exp Med (1971) 8.22
Binding of sheep red blood cells to a large population of human lymphocytes. Nature (1971) 7.67
A receptor for antibody on B lymphocytes. I. Method of detection and functional significance. J Exp Med (1972) 7.47
The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis. J Exp Med (1966) 6.50
Rosette formation by peripheral lymphocytes. Clin Exp Immunol (1970) 6.34
Rosette-formation between human lymphocytes and sheep red cells not involving immunoglobulin receptors. Int Arch Allergy Appl Immunol (1970) 5.92
Immunoglobulins on the surface of lymphocytes. II. The bone marrow as the main source of lymphocytes with detectable surface-bound immunoglobulin. J Exp Med (1971) 5.43
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Rapid preparation of lymphocytes for tissue-typing. Lancet (1969) 5.11
Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia. J Clin Invest (1971) 4.98
COMPONENTS OF GUINEA PIG COMPLEMENT. I. SEPARATION OF A SERUM FRACTION ESSENTIAL FOR IMMUNE HEMOLYSIS AND IMMUNE ADHERENCE. J Exp Med (1963) 4.46
Receptor sites for complement on certain human peripheral blood lymphocytes. J Immunol (1970) 4.09
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest (1972) 3.64
Theta-bearing and complement-receptor lymphocytes are distinct populations of cells. Science (1971) 3.16
Binding of sheep erythrocytes to human lymphocytes. A probable marker of T lymphocytes. Scand J Immunol (1972) 2.87
Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood (1972) 2.25
[Membrane monoclonal immunoglobulins in chronic lymphoid leukemia]. Rev Eur Etud Clin Biol (1971) 1.91
Bone marrow origin of complement-receptor lymphocytes. Eur J Immunol (1971) 1.80
Rosette formation, a test for cellular immunity. Trans Assoc Am Physicians (1971) 1.64
Complement and tumor immunology. Adv Cancer Res (1971) 1.57
Immunoglobulins on the surface of lymphocytes. V. Quantitative studies on the question of whether immunoglobulins are associated with T cells in the mouse. J Immunol (1972) 1.26
Immunoglobulins on the surface of lymphocytes. I. Distribution and quantitation. J Exp Med (1971) 8.22
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Immunoglobulins on the surface of lymphocytes. II. The bone marrow as the main source of lymphocytes with detectable surface-bound immunoglobulin. J Exp Med (1971) 5.43
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia. J Clin Invest (1971) 4.98
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
A molecular concept of immune cytolysis. Arch Pathol (1966) 3.90
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol (1984) 3.72
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol (1981) 3.38
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes. J Exp Med (1974) 3.21
Structure and function of immunoglobulin A. Prog Allergy (1972) 3.14
Antigen presentation by normal B cells, B cell tumors, and macrophages: functional and biochemical comparison. J Immunol (1982) 3.08
Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med (1977) 2.98
A subclass of human gamma-A-globulins (gamma-A2) which lacks the disulfied bonds linking heavy and light chains. J Exp Med (1968) 2.98
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation. Proc Natl Acad Sci U S A (1977) 2.80
Membrane complement receptors specific for bound fragments of C3. Adv Immunol (1985) 2.80
Specificity of human lymphocyte complement receptors. J Exp Med (1975) 2.77
Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol (1981) 2.74
Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A (1989) 2.73
Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol (1982) 2.68
The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med (1973) 2.68
Immunological self, nonself discrimination. Science (1987) 2.59
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A (1986) 2.42
Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol (1996) 2.41
Protein A reactivity with mouse immunoglobulins. Structural relationship between some mouse and human immunoglobulins. J Immunol (1970) 2.38
Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med (1982) 2.36
Thymus-derived (T) cell immunoglobulins. Presence of a receptor site for IgG and absence of large amounts of "buried" Ig determinants on T cells. J Exp Med (1972) 2.35
Immunoglobulins on the surface of lymphocytes. 3. Bursal origin of surface immunoglobulins on chicken lymphocytes. J Immunol (1971) 2.33
A new mouse immunoglobulin: IgG3. J Exp Med (1971) 2.27
Requirements for the processing of antigens by antigen-presenting B cells. I. Functional comparison of B cell tumors and macrophages. J Immunol (1982) 2.25
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Cryoimmunoglobulins. Semin Hematol (1973) 2.18
Analysis of the different types of leukocyte membrane complement receptors and their interaction with the complement system. J Immunol Methods (1980) 2.17
p150/95, Third member of the LFA-1/CR3 polypeptide family identified by anti-Leu M5 monoclonal antibody. Eur J Immunol (1985) 2.14
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin. J Exp Med (1980) 1.96
B cells as antigen-presenting cells: the requirement for B cell activation. J Immunol (1983) 1.93
Autologous peptides constitutively occupy the antigen binding site on Ia. Science (1988) 1.92
Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest (1988) 1.92
Antigen presentation by splenic B cells: resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses. J Immunol (1985) 1.91
Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody. Proc Natl Acad Sci U S A (1981) 1.86
Structural analysis of peptides capable of binding to more than one Ia antigen. J Immunol (1989) 1.85
Studies on receptors for IgG on epithelial cells of the rat intestine. J Immunol (1977) 1.82
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A (1974) 1.80
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today (1996) 1.79
Sharing of individual antigenic determinants between a gamma G and a gamma M protein in the same myeloma serum. Proc Soc Exp Biol Med (1970) 1.79
Studies on the structure of mouse gamma-A myeloma proteins. Biochemistry (1968) 1.78
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol (1993) 1.78
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol (1991) 1.75
Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol (1994) 1.73
Human monoclonal gamma G-cryoglobulins with anti-gamma-globulin activity. J Clin Invest (1968) 1.72
Antigen recognition by T cells and B cells: recognition of cross-reactivity between native and denatured forms of globular antigens. Clin Immunol Immunopathol (1980) 1.72
Catabolism of human gammaG-immunoglobulins of different heavy chain subclasses. I. Catabolism of gammaG-myeloma proteins in man. J Clin Invest (1968) 1.71
MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol (1992) 1.71
Membrane receptors of mouse leukocytes. II. Sequential expression of membrane receptors and phagocytic capacity during leukocyte differentiation. J Exp Med (1978) 1.69
Specificity of recombination of H and L chains from human gamma-G-myeloma proteins. J Exp Med (1965) 1.69
Structural studies of human gamma D myeloma protein. Biochemistry (1970) 1.66
Nonspecific complement activation by streptococcal structures. II. Properdin-independent initiation of the alternate pathway. J Exp Med (1976) 1.64
Capacity of intact proteins to bind to MHC class II molecules. J Immunol (1989) 1.63
I-Ad-binding peptides derived from unrelated protein antigens share a common structural motif. J Immunol (1988) 1.61
Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol (2001) 1.60
Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A (1994) 1.56
The sequential appearance of Ia-like antigens and two different complement receptors during the maturation of human neutrophils. J Exp Med (1978) 1.56
Dissociation between increased surface expression of gp165/95 and homotypic neutrophil aggregation. J Immunol (1988) 1.56
IgD: a major immunoglobulin on the surface of lymphocytes from patients with chronic lymphatic leukemia. J Immunol (1974) 1.56
The cytophilic activity of human immunoglobulins. J Immunol (1970) 1.55
Mitogen activation of human chronic lymphatic leukemia cells. I. Synthesis and secretion of immunoglobulin. J Immunol (1977) 1.52
Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol (1996) 1.52
Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc Natl Acad Sci U S A (1988) 1.51